Topical endotracheal mitomycin C as a complementary treatment for endoscopic treatment of recurrent laryngotracheal stenosis

To describe the preparation of topical endotracheal mitomycin C and the clinical outcomes of four patients with recurrent and severe laryngotracheal stenosis (LTS) treated with adjuvant topical mitomycin C. Literature review to determine the concentration and method of preparation of topical mitomyc...

Full description

Saved in:
Bibliographic Details
Published in:Farmacia hospitalaria 2011-01, Vol.35 (1), p.32-35
Main Authors: Cortés de Miguel, S, Cabeza Barrera, J, Gallardo Medina, M, Cassini Gómez de Cádiz, L F, Salmerón-García, A, Rodríguez Lucas, F
Format: Article
Language:eng ; spa
Subjects:
Administration, Topical
Adult
Combined Modality Therapy
Female
Humans
Laryngoscopy
Laryngostenosis - complications
Laryngostenosis - therapy
Male
Middle Aged
Mitomycin - administration & dosage
Recurrence
Tracheal Stenosis - complications
Tracheal Stenosis - therapy
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To describe the preparation of topical endotracheal mitomycin C and the clinical outcomes of four patients with recurrent and severe laryngotracheal stenosis (LTS) treated with adjuvant topical mitomycin C. Literature review to determine the concentration and method of preparation of topical mitomycin C for endotracheal use. Review of clinical histories. We established a concentration of 0.4 mg/ml topical mitomycin C for the treatment of laryngotracheal stenosis. In the treated cases, we applied a 0.4 mg/ml solution to the wound site following laser surgery and dilatation with bronchoscope. Three patients remain asymptomatic from a respiratory perspective, and treatment failed in one case. LTS treatment is complex due to the continuous development of granulation tissue and fibrosis following injury to the airways. Topical mitomycin C seems to be the ideal adjuvant agent thanks to its powerful antifibrotic effects.
ISSN:1130-6343
DOI:10.1016/j.farma.2010.04.002